Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Fineline Cube Apr 27, 2026
Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026
Company Medical Device

Microport EP Medtech’s Cryoablation Catheter and Equipment Approved as Innovative Devices in China

Fineline Cube Aug 25, 2023

Shanghai Microport EP Medtech Co., Ltd has announced that its balloon type cryoablation catheter and...

Company Drug

CSPC Pharmaceutical’s Generic Entresto Approved in China for Heart Failure Treatment

Fineline Cube Aug 25, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Swiss...

Company Drug

Akeso Biopharma’s Ivonescimab Heads for Priority Review for NSCLC Treatment

Fineline Cube Aug 25, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that its bispecific antibody (BsAb) ivonescimab (AK112), targeting...

Company

3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing

Fineline Cube Aug 25, 2023

China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of...

Company Drug

GSK’s Shingrix Proves 100% Efficacy in Phase IV Trial for Chinese Patients

Fineline Cube Aug 24, 2023

UK-based pharmaceutical giant GSK plc (NYSE: GSK) has released efficacy data for its shingles vaccine,...

Company Deals

ImmuneOnco Biopharmaceuticals Launches IPO to Raise HKD 319 Million on Hong Kong Stock Exchange

Fineline Cube Aug 24, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) is poised to raise HKD 319 million (USD...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Approved by China’s NMPA for NSCLC Treatment

Fineline Cube Aug 24, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that it has received market approval...

Company Drug

Hinova Pharmaceuticals’ HP518 for mCRPC Accepted for Review by China’s NMPA

Fineline Cube Aug 24, 2023

Chengdu-based biotech company Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the National Medical Products...

Company Deals

Labway Clinical Laboratory Partners with 10x Genomics for Precision Medicine Advancements

Fineline Cube Aug 24, 2023

Shanghai Labway Clinical Laboratory Co., Ltd., a leading provider of medical laboratory and pathological diagnostic...

Company Drug

Akeso Biopharma’s Ebdarokimab (AK101) NDA Accepted for Review by China’s CDE

Fineline Cube Aug 24, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that the New Drug Application (NDA) for its...

Policy / Regulatory

Beijing Drafts Regulations for Internet Diagnosis and Treatment, Prohibits AI Prescriptions

Fineline Cube Aug 24, 2023

The Beijing Municipal Health Commission has released the “Implementation Measures for Internet Diagnosis and Treatment...

Company

Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials

Fineline Cube Aug 24, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half...

Company Drug

Eli Lilly’s Retevmo Meets Primary Endpoint in Phase III Trial for RET-mutant Medullary Thyroid Cancer

Fineline Cube Aug 24, 2023

Eli Lilly (NYSE: LLY) has announced that its Phase III trial for the RET kinase...

Company Drug

FDA Grants Priority Review to Pfizer and Astellas’ Xtandi for High-Risk Prostate Cancer

Fineline Cube Aug 24, 2023

The US Food and Drug Administration (FDA) has granted priority review status to the submission...

Company Legal / IP

Scott-Moncrieff & Associates Preparing 50 Cases Against AstraZeneca Over Vaccine Concerns

Fineline Cube Aug 24, 2023

Scott-Moncrieff & Associates, a UK-based law firm, has disclosed that it is preparing nearly 50...

Company Drug

Nanjing F&S Pharmatech Secures First Generic Approval for Novartis’s Entresto in China

Fineline Cube Aug 24, 2023

Nanjing F&S Pharmatech Co., Ltd, a China-based pharmaceutical company, has announced that it has received...

Company

WuXi Biologics Reports 17.8% Revenue Growth and Expands Service Scope in H1 2023

Fineline Cube Aug 24, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...

Company

Johnson & Johnson Completes Spinoff of Kenvue as Independent Company

Fineline Cube Aug 24, 2023

Global healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has completed the separation of its...

Company

Everest Medicines Reports Q1 2023 Revenue Growth and Pipeline Progress

Fineline Cube Aug 24, 2023

China-based Everest Medicines (HKG: 1952) has announced its financial and corporate update for the first...

Company Drug

Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Ankylosing Spondylitis Phase II Study

Fineline Cube Aug 23, 2023

China-based Lynk Pharmaceuticals Co., Ltd has announced positive topline results from the Phase II clinical...

Posts pagination

1 … 475 476 477 … 657

Recent updates

  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.